Hostname: page-component-857557d7f7-ktsnh Total loading time: 0 Render date: 2025-11-26T00:21:37.939Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacological and Biochemical Evidence for the Existence of Two Categories of Dopamine Receptor

Published online by Cambridge University Press:  18 September 2015

J.W. Kebabian ,
M. Beaulieu  and
Y. Itoh
M. Beaulieu
Affiliation:
Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke NIH, Bethesda, MD
Y. Itoh
Affiliation:
Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke NIH, Bethesda, MD
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Evidence supporting the validity of the ‘two dopamine receptor’ hypothesis is presented. The availability of the ‘first generation’ of selective agonists and antagonists of the D-1 and the D-2 dopamine receptors provides pharmacological support for the hypothesis. The demonstration that stimulation of the D-2 receptor either inhibits or has no effect upon adenylate cyclase activity while stimulation of the D-1 receptor enhances cAMP formation provides biochemical support for the hypothesis. Finally, binding assays demonstrating two affinity states for the D-1 and the D-2 receptors are briefly discussed.

Information

Type
1. Neurotransmitters and the Pharmacology of the Basal Ganglia
Information
Canadian Journal of Neurological Sciences , Volume 11 , Issue S1: Current Concepts and Controversies in Parkinson’s Disease , February 1984 , pp. 114 - 117
Copyright
Copyright © Canadian Neurological Sciences Federation 1984

References

Brown, EM, Carroll, RJ, Aurbach, GD (1977) Dopaminergic stimulation of cyclic AMP accumulation and parathyroid hormone release from dispersed bovine parathyroid cells. Proc. Natl. Acad. Sci. (USA) 74:4210–4213.CrossRefGoogle ScholarPubMed
Brown, EM, Attie, MF, Reen, S, Gardner, DG, Kebabian, JW, Aurbach, GD (1980) Characterization of dopaminergic receptors in dispersed bovine parathyroid cells, Mol. Pharmacol. 18:335–340.Google ScholarPubMed
Cote, TE, Grewe, CW, Tsuruta, K, Stoof, JC, Eskay, RL, Kebabian, JW (1982) D-2 dopamine receptor-mediated inhibition of adenylate cyclase activity in the intermediate lobe of the rat pituitary gland requires GTP. Endocrinology 110:812–819.CrossRefGoogle Scholar
Denef, C, Follenbouckt, J-J (1978) Differential effects of dopamine antagonists on prolactin secretion from cultured rat pituitary cells, Life Sci. 23:431–436.CrossRefGoogle ScholarPubMed
Douglas, WW, Taraskevich, PS (1978) Actions potentials in gland cells of rat pituitary pars intermedia: inhibition by dopamine, an inhibitor of MSH secretion, J. Physiol (London) 285:171–184.CrossRefGoogle ScholarPubMed
Douglas, WW, Taraskevich, PS (1980) Calcium component to action potentials in rat pars intermedia cells. J. Physiol. (London) 309:623–630.CrossRefGoogle ScholarPubMed
Douglas, WW, Taraskevich, PS (1982) Slowing effects of dopamine and calcium-channel blockers on frequency of sodium spikes in rat pars intermedia cells, J. Physiol. (London) 326:201–211.CrossRefGoogle ScholarPubMed
Euvrard, C, Ferland, L, Di Paolo, T, Beaulieu, M, Labrie, F, Oberlander, C, Raynaud, JP, Boissier, JR (1980) Activity of two new potent dopaminergic agonists at the striatal and anterior pituitary levels, Neuropharmacology 19:379–386.CrossRefGoogle ScholarPubMed
Grewe, CW, Frey, EA, Cote, TE, Kebabian, JW (1982) YM-09151–2: A potent antagonist for a peripheral D2-dopamine receptor. European J. Pharmacol. 81:149–152.CrossRefGoogle ScholarPubMed
Hahn, RA, Wardell, JR, Sarau, HM, Ridley, PT (1982) Characterization of the peripheral and central effects of SK & F 82526, a novel dopamine receptor agonist. J. Pharmacol. Exp. Ther. 223:305–313.Google ScholarPubMed
Hyttel, J (1983) SCH 23390–The first selective D-1 antagonist. European J. Pharmacol. 91:153–154.CrossRefGoogle Scholar
Iorio, LC, Barnett, A, Leitz, FH, Houser, VP, Korduba, CA (1983) SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J. Pharmacol. Exp. Ther. 226:462–468.Google ScholarPubMed
Kaiser, C (1983) Stereoisomeric probes of the dopamine receptor. In: Dopamine Receptors, American Chemical Society Symposium Series 224 (Kaiser, C and Kebabian, JW, eds.), American Chemical Society Press, Washington, pp. 223–246.Google ScholarPubMed
Kebabian, JW and Calne, DB (1979) Multiple receptors for dopamine. Nature 277: 93–96.CrossRefGoogle ScholarPubMed
Kebabian, JW, Calne, DB, Kebabian, PR (1977) Lergotrile mesylate: An in vivo dopamine agonist which blocks dopamine receptors in vitro. Communications in Psychopharmacol. 1:311–318.Google Scholar
Laduron, PM (1983) Commentary: Dopamine-sensitive adenylate cyclase as a receptor site, In: Dopamine Receptors (Kebabian, JW and Kaiser, C, eds.), American Chemical Society Symposium Series 224, American Chemical Society Press, Washington, D.C., pp. 22–28, 1983.Google Scholar
Leff, SE, Creese, I (1983) Dopamine receptors re-explained. Trends in Pharmacological Sci., in press.CrossRefGoogle Scholar
Meunier, H, Labrie, F (1982) The dopamine receptor in the intermediate lobe of the rat pituitary gland is negatively coupled to adenylate cyclase. Life Sci. 30:963–968.CrossRefGoogle ScholarPubMed
Meunier, H, Lefevre, G, Dumont, D, Labrie, F (1982) CRF stimulates alpha-MSH secretion and cyclic AMP accumulation in rat pars intermedia cells. Life Sci. 31:2129–2135.CrossRefGoogle ScholarPubMed
Miyazaki, K, Goldman, ME, Kebabian, JW (1984) Forskolin stimulates adenylate cyclase activity, adenosine 3’, 5’ monophosphate production and peptide release from the intermediate lobe of the rat pituitary gland. Endocrinology: in press.CrossRefGoogle Scholar
Munemura, M, Eskay, RL, Kebabian, JW (1980) Release of a-melanocyte-stimulating hormone from dispersed cells of the intermediate lobe of the rat pituitary gland: involvement of catecholamines and adenosine 3’, 5’-monophosphate. Endrocrinology 106:1795–1803.CrossRefGoogle Scholar
Onali, P, Schwartz, JP, Costa, E (1981) Dopaminergic modulation of adenylate cyclase stimulated by vasoactive intestinal peptide in anterior pituitary. Proc. Natl. Acad. Sci. (USA) 78:6531–6534.CrossRefGoogle ScholarPubMed
Pieri, L, Keller, HH, Burkard, W, DaPrada, M (1978) Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis. Nature 272:278–280.CrossRefGoogle ScholarPubMed
Seeman, P (1980) Brain dopamine receptors, Pharmacol. Rev. 32:229–313.Google ScholarPubMed
Reuter, H (1983) Calcium channel modulation by neurotransmitters, enzymes and drugs. Nature 301:560–574.CrossRefGoogle ScholarPubMed
Setler, PE, Sarau, HM, Zirkle, CL, Saunders, HL (1978) The central effects of a novel dopamine agonist, Eur. J. Pharmacol. 50:419–430.CrossRefGoogle ScholarPubMed
Sibley, DR, DeLean, A, Creese, I (1982) Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. J. Biol. Chem. 257:6351–6361.CrossRefGoogle ScholarPubMed
Sokoloff, P, Martes, MP, Schwartz, JC (1980) Three classes of dopamine receptor (D-2, D-3, D-4) identified by binding studies with 3H-apomorphine and 3H-domperidone. Nauyn-Schmiedebergs Arch. Pharmacol. 315:89–102.CrossRefGoogle ScholarPubMed
Stoof, JC (1983) Dopamine receptors in the neostriatum: Biochemical and physiological studies, In: Dopamine Receptors, American Chemical Society Symposium Series 224 (Kaiser, C and Kebabian, JW, eds.), American Chemical Society Press, Washington, pp. 117–145.Google Scholar
Stoof, JC, Kebabian, JW (1981) Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 294:366–368.CrossRefGoogle ScholarPubMed
Stoof, JC, Kebabian, JW (1982) Independent in vitro regulation by the D-2 dopamine receptor of dopamine-stimulated efflux of cyclic AMP and K+-stimulated release of acetycholine from rat neostriatum, Brain Res. 250:263–270.CrossRefGoogle Scholar
Titus, RD, Kornfeld, EC, Jones, ND, Clemens, JA, Smalstig, EB, Fuller, RW, Hahn, RA, Hynes, MD, Mason, NR.Wong, DT, Foreman, MM (1983) The resolution and absolute configuration of an ergoline-related dopamine agonist, trans-4, 4a, 5, 6, 7, 8, 8a, 9-octahydro-5-propyl-lH (or 2H)-pyrazolo [3, 4-g] quinoline, J. Med. Chem. 26:1112–1116.CrossRefGoogle Scholar
Tsuruta, K, Frey, EA, Grewe, CW, Cote, TE, Eskay, RL, Kebabian, JW (1981) Evidence that LY-141865 specifically stimulates the D-2 dopamine receptor. Nature 292:463–465.CrossRefGoogle ScholarPubMed
Tsuruta, K, Grewe, CW, Cote, TE, Eskay, RL, Kebabian, JW (1982) Coordinated action of calcium ion and cyclic adenosine 31, 5’ monophosphate upon the release of a-melanocyte stimulating hormone from the intermediate lobe of the rat pituitary gland. Endocrinology 110:1133–1140.CrossRefGoogle Scholar